Success in finding replacement blood would be a major step forward in alleviating the shortage of blood. Finding a viable blood substitute has been encouraging.
Despite the last 35 years have seen previous efforts were not due to toxicity problems, a strategy to identify and eliminate sources of toxicity seems promising. HemoBioTech, Dallas-based pharmaceutical company is to create a viable blood substitute, called HemoTech, which is expected, with the blood and should serve more than 180 days to 42 days in blood.
Of the blood substitute is composed of chemically modified bovine hemoglobin. Natural blood hemoglobin binds with oxygen in the blood through the lungs and out of cells throughout the body. HemoTech working on the same principle, using oxygen in the blood to cells and has the additional advantage, in fact, compel the production of red blood cells.
Blood Heal
Researchers University of Texas Medical Sciences Center HemoTech development began in 1985. Research and Development was founded by two leading bodies of the replacement of blood, Dr. Mario Feola and Jan Simoni.
In a limited clinical study, nine patients with sickle-cell anemia infused with the replacement of blood, 25 percent of the patients blood volume. This limits the patients in clinical research have led to significant improvements, and demonstrated that the blood substitute, as an efficient transport of oxygen by people without the toxic side effects.
"The world needs a viable substitute for human blood, more than ever," said Arthur Bollon, Ph.D., Chairman, President and Chief Executive Officer, with headquarters in Dallas.
"Some scientists believe that a viable blood substitute would be a medical breakthrough that could save millions of lives every year."